Submit Deal

NEUROCRINE GROUP LTD (FORMELY DIURNAL GROUP PLC)

Summary

Neurocrine Group Limited is a rare disease-focused pharmaceutical company and the former Diurnal Group, operating as Neurocrine Biosciences’ European rare commercial business.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 96 M

Avg. Deal Size£ 48 M

Market Context

Senior Management

Richard Bungay
Interim CEO
Kyle Gano
Chief Business Development and Strategy Officer
Anders Härfstrand
Non-Executive Chairman

Sort

30 Aug 2022|United Kingdom|Pharmaceuticals

Target: NEUROCRINE GROUP LTD (FORMELY DIURNAL GROUP PLC)

Bidder: NEUROCRINE BIOSCIENCES

8 Service Providers

5 Target | 3 Bidder

36 Dealmakers

12 Target | 24 Bidder

£ 48 M

Value

08 Jan 2026|United Kingdom|Pharmaceuticals

Target: NEUROCRINE GROUP LTD (FORMELY DIURNAL GROUP PLC)

Bidder: IMMEDICA PHARMA AB

4 Service Providers

1 Target | 3 Bidder

4 Dealmakers

1 Target | 3 Bidder

£ 48 M

Value